Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease
Cynthia Kwan, Imane Frouni, Dominique Bédard, et al.
European Journal of Pharmacology (2020) Vol. 871, pp. 172914-172914
Closed Access | Times Cited: 21

Showing 21 citing articles:

Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson’s Disease
E. Maruthi Prasad, Shih‐Ya Hung
Antioxidants (2020) Vol. 9, Iss. 10, pp. 1007-1007
Open Access | Times Cited: 87
Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson’s Disease and Adverse Effects of L-DOPA
Ana Muñoz, Andrea López-López, Carmen M. Labandeira, et al.
Frontiers in Neuroanatomy (2020) Vol. 14
Open Access | Times Cited: 55
Restoration and targeting of aberrant neurotransmitters in Parkinson's disease therapeutics
Divya Yadav, Pravir Kumar
Neurochemistry International (2022) Vol. 156, pp. 105327-105327
Closed Access | Times Cited: 32
Neuroprotective potential of Mentha piperita extract prevents motor dysfunctions in mouse model of Parkinson’s disease through anti-oxidant capacities
Rabia Anjum, Chand Raza, Mehwish Faheem, et al.
PLoS ONE (2024) Vol. 19, Iss. 4, pp. e0302102-e0302102
Open Access | Times Cited: 7
Ondansetron attenuates cisplatin-induced behavioral and cognitive impairment through downregulation of NOD-like receptor inflammasome pathway
Mennat-Allah M. Hassan, Sara A. Wahdan, Reem N. El‐Naga, et al.
Toxicology and Applied Pharmacology (2024) Vol. 485, pp. 116875-116875
Closed Access | Times Cited: 5
The anti-dyskinetic effect of the clinic-ready mGluR2 positive allosteric modulator AZD8529 in the 6-OHDA-lesioned rat
Woojin Kang, W.–S. Kang, Fleur Gaudette, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Phytoconstituents Targeting the Serotonin 5-HT3 Receptor: Promising Therapeutic Strategies for Neurological Disorders
Likhit Akotkar, Urmila Aswar, Ankit Ganeshpurkar, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 6, pp. 1694-1710
Open Access | Times Cited: 3
Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence
Philippe De Deurwaerdère, Abdeslam Chagraoui, Giuseppe Di Giovanni
Progress in brain research (2021), pp. 161-264
Closed Access | Times Cited: 18
Effect of glycine transporter 1 inhibition with bitopertin on parkinsonism and L-DOPA induced dyskinesia in the 6-OHDA-lesioned rat
Imane Frouni, Woojin Kang, Dominique Bédard, et al.
European Journal of Pharmacology (2022) Vol. 929, pp. 175090-175090
Open Access | Times Cited: 9
Phylogenetic analyses of 5-hydroxytryptamine 3 (5-HT3) receptors in Metazoa
Santosh T. R. B. Rao, Ilona Turek, Helen Irving
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0281507-e0281507
Open Access | Times Cited: 5
Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset
Cynthia Kwan, Stephen G. Nuara, Dominique Bédard, et al.
Neuropharmacology (2020) Vol. 182, pp. 108386-108386
Closed Access | Times Cited: 14
Dyskinesia and Parkinson’s disease: animal model, drug targets, and agents in preclinical testing
Valentina Cesaroni, Fabio Blandini, Silvia Cerri
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 10, pp. 837-851
Closed Access | Times Cited: 8
Activation of mGlu2/3 receptors with the orthosteric agonist LY-404,039 alleviates dyskinesia in experimental parkinsonism
Woojin Kang, Imane Frouni, Cynthia Kwan, et al.
Behavioural Pharmacology (2024)
Closed Access | Times Cited: 1
Autoradiographic labelling of metabotropic glutamate type 2/3 receptors in the hemi-parkinsonian rat brain
Esther Kim, Imane Frouni, Judy Shaqfah, et al.
Journal of Chemical Neuroanatomy (2024) Vol. 138, pp. 102422-102422
Open Access | Times Cited: 1
Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases
Cencan Xing, Hongyu Chen, Wangyu Bi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13446-13446
Open Access | Times Cited: 1
Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat
Cynthia Kwan, Imane Frouni, Dominique Bédard, et al.
Behavioural Pharmacology (2020) Vol. 32, Iss. 1, pp. 43-53
Closed Access | Times Cited: 6
The Role of the Serotonergic System of the Brain in the Pathogenesis of Parkinson’s Disease
Ahsas Goyal, Wasim Chisti, Aanchal Verma, et al.
Neurochemical Journal (2023) Vol. 17, Iss. 1, pp. 30-41
Closed Access | Times Cited: 1
Ondansetron for the treatment of Parkinson’s disease psychosis: Rationale and literature review
Abhishek Lenka, Jaslovleen Kaur, J. Isaacson, et al.
Annals of Movement Disorders (2023) Vol. 6, Iss. 2, pp. 72-78
Open Access | Times Cited: 1
Autoradiographic labelling of 5-HT3 receptors in the hemi-parkinsonian rat brain
Cynthia Kwan, Catherine Lévesque, Dominique Bédard, et al.
Neuroscience Research (2021) Vol. 177, pp. 135-144
Closed Access | Times Cited: 3
Role of P11 through serotonergic and glutamatergic pathways in LID
Alireza Noori, Kousha Farhadi, Yasmin Mohtasham Kia, et al.
Molecular Biology Reports (2023) Vol. 50, Iss. 5, pp. 4535-4549
Closed Access

Adjia Hamadjida, Rigobert Espoir, Ayissi Mbomo, et al.
International Journal of Pharmaceutical Sciences and Research (2023) Vol. 14, Iss. 10
Open Access
Page 1

Scroll to top